Pulmonx share price today

(LUNG)

Pulmonx share price is $6.69 & ₹574.07 as on 7 Jan 2025, 2.30 'hrs' IST

$6.69

▲

0.14

(2.14%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Pulmonx share price in Dollar and Rupees. Guide to invest in Pulmonx stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Pulmonx, along with analyst recommendations, forecasts, and comprehensive financials.

Pulmonx share price movements

Today's Low: $6.60
Today's High: $6.86
$6.69
1.35%
Downside
Day's Volatility :3.72%
Upside
2.41%
52 Weeks Low: $5.46
52 Weeks High: $14.84
$6.69
18.39%
Downside
52 Weeks Volatility :63.2%
Upside
54.9%

Pulmonx Returns

Period	Pulmonx Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.61%	-8.4%	0.0%
6 Months	2.5%	-3.8%	0.0%
1 Year	-46.66%	-0.1%	0.0%
3 Years	-78.38%	2.9%	-19.8%

Pulmonx Key Statistics

in dollars & INR

Previous Close	$6.55
Open	$6.6
Today's High	$6.855
Today's Low	$6.6
Market Capitalization	$268.1M
Today's Volume	$112.9K
52 Week High	$14.835
52 Week Low	$5.46
Revenue TTM	$79.3M
EBITDA	$-55.0M
Earnings Per Share (EPS)	$-1.47
Profit Margin	-72.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-51.99%

How to invest in Pulmonx from India?

It is very easy for Indian residents to invest directly in Pulmonx from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Pulmonx stock in both Indian Rupees (INR) and US Dollars (USD). Search for Pulmonx or LUNG on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Pulmonx or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Pulmonx shares which would translate to 0.128 fractional shares of Pulmonx as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Pulmonx, in just a few clicks!

Returns in Pulmonx for Indian investors in Rupees

Investment Value

₹1,00,000

Pulmonx investment value today

Current value as on today

₹57,701

Returns

₹42,299

(-42.3%)

Returns from Pulmonx Stock

₹45,521 (-45.52%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Pulmonx

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Pulmonx on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 0% more investors are searching Pulmonx in the last 30 days versus the previous period.

Global Institutional Holdings in Pulmonx

FMR Inc
14.87%
PRIMECAP Management Company
14.37%
Morgan Stanley - Brokerage Accounts
9.60%
BlackRock Inc
6.76%
Vanguard Group Inc
5.77%
Deutsche Bank AG
2.84%

Analyst Recommendation on Pulmonx

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Pulmonx(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Pulmonx

What analysts predicted

Upside of 78.13%

Current:

$6.69

Target:

$11.92

Insights on Pulmonx

Price Movement
In the last 7 days, LUNG stock has moved down by -2.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 20.78M → 20.38M (in $), with an average decrease of 1.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -15.32M → -14.14M (in $), with an average increase of 8.4% per quarter
LUNG vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 55.9% return, outperforming this stock by 101.2%
LUNG vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 112.9% return, outperforming this stock by 192.5%
Price to Sales
ForLUNG every $1 of sales, investors are willing to pay $3.2, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Pulmonx Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$20.0M	-
Net Income	$-18.5M	↑ 244.16%
Net Profit Margin	-92.38%	-

	FY19	Y/Y Change
Revenue	$32.6M	↑ 62.94%
Net Income	$-20.7M	↑ 12.04%
Net Profit Margin	-63.52%	↑ 28.86%

	FY20	Y/Y Change
Revenue	$32.7M	↑ 0.42%
Net Income	$-32.2M	↑ 55.68%
Net Profit Margin	-98.47%	↓ 34.95%

	FY21	Y/Y Change
Revenue	$48.4M	↑ 47.91%
Net Income	$-48.7M	↑ 50.98%
Net Profit Margin	-100.51%	↓ 2.04%

	FY22	Y/Y Change
Revenue	$53.7M	↑ 10.84%
Net Income	$-58.9M	↑ 21.09%
Net Profit Margin	-109.8%	↓ 9.29%

	FY23	Y/Y Change
Revenue	$68.7M	↑ 27.98%
Net Income	$-60.8M	↑ 3.26%
Net Profit Margin	-88.6%	↑ 21.2%

	Q2 FY23	Q/Q Change
Revenue	$17.2M	↑ 18.29%
Net Income	$-16.2M	↑ 2.11%
Net Profit Margin	-94.19%	↑ 14.93%

	Q3 FY23	Q/Q Change
Revenue	$17.7M	↑ 2.76%
Net Income	$-14.9M	↓ 8.0%
Net Profit Margin	-84.33%	↑ 9.86%

	Q4 FY23	Q/Q Change
Revenue	$19.3M	↑ 9.11%
Net Income	$-13.9M	↓ 6.79%
Net Profit Margin	-72.04%	↑ 12.29%

	Q1 FY24	Q/Q Change
Revenue	$18.9M	↓ 2.2%
Net Income	$-13.7M	↓ 1.0%
Net Profit Margin	-72.92%	↓ 0.88%

	Q2 FY24	Q/Q Change
Revenue	$20.8M	↑ 10.23%
Net Income	$-15.3M	↑ 11.47%
Net Profit Margin	-73.74%	↓ 0.82%

	Q3 FY24	Q/Q Change
Revenue	$20.4M	↓ 1.91%
Net Income	$-14.1M	↓ 7.71%
Net Profit Margin	-69.38%	↑ 4.36%

	FY18	Y/Y Change
Profit	$12.3M	-

	FY19	Y/Y Change
Profit	$22.4M	↑ 82.44%

	FY20	Y/Y Change
Profit	$21.2M	↓ 5.41%

	FY21	Y/Y Change
Profit	$35.6M	↑ 68.05%

	FY22	Y/Y Change
Profit	$39.9M	↑ 11.89%

	FY23	Y/Y Change
Profit	$50.8M	↑ 27.31%

	Q2 FY23	Q/Q Change
Profit	$12.7M	↑ 20.26%

	Q3 FY23	Q/Q Change
Profit	$13.0M	↑ 2.32%

	Q4 FY23	Q/Q Change
Profit	$14.3M	↑ 9.76%

	Q1 FY24	Q/Q Change
Profit	$14.0M	↓ 2.25%

	Q2 FY24	Q/Q Change
Profit	$15.3M	↑ 9.51%

	Q3 FY24	Q/Q Change
Profit	$15.0M	↓ 1.84%

	FY18	Y/Y Change
Operating Cash Flow	$-18.4M	↑ 296.63%
Investing Cash Flow	$200.0K	↓ 846.24%
Financing Cash Flow	$12.1M	↑ 129.78%

	FY19	Y/Y Change
Operating Cash Flow	$-20.8M	↑ 12.89%
Investing Cash Flow	$-14.2M	↓ 7216.5%
Financing Cash Flow	$45.6M	↑ 276.58%

	FY20	Y/Y Change
Operating Cash Flow	$-30.6M	↑ 47.52%
Investing Cash Flow	$12.7M	↓ 189.19%
Financing Cash Flow	$234.8M	↑ 414.77%

	FY21	Y/Y Change
Operating Cash Flow	$-41.4M	↑ 35.11%
Investing Cash Flow	$-46.3M	↓ 464.38%
Financing Cash Flow	$4.5M	↓ 98.1%

	FY22	Y/Y Change
Operating Cash Flow	$-45.1M	↑ 8.93%
Investing Cash Flow	$-4.2M	↓ 90.87%
Financing Cash Flow	$2.5M	↓ 44.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 37.59%
Investing Cash Flow	$-813.0K	↓ 241.64%
Financing Cash Flow	$92.0K	↓ 99.56%

Pulmonx Technicals Summary

Sell

Neutral

Buy

Pulmonx is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Pulmonx Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Pulmonx Corp	2.83%	2.5%	-46.66%	-78.38%	-83.34%
Stryker Corporation	-5.14%	7.73%	20.51%	37.02%	70.83%
Boston Scientific Corp.	2.22%	18.53%	55.24%	113.84%	98.4%
Edwards Lifesciences Corp.	4.25%	-20.93%	-2.33%	-38.47%	-5.21%
Abbott Laboratories	-0.93%	11.99%	1.27%	-15.84%	31.69%
Medtronic Plc	-3.59%	5.29%	-6.49%	-23.36%	-31.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Pulmonx Corp	NA	NA	NA	-1.56	-0.52	-0.2	NA	2.38
Stryker Corporation	38.59	38.59	2.51	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	73.82	73.82	1.62	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	28.0	28.0	6.67	2.54	0.19	0.11	NA	16.18
Abbott Laboratories	34.38	34.38	2.19	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.43	24.43	1.46	5.45	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Pulmonx Corp	Buy	$268.1M	-83.34%	NA	-72.01%
Stryker Corporation	Buy	$137.3B	70.83%	38.59	16.34%
Boston Scientific Corp.	Buy	$131.6B	98.4%	73.82	11.26%
Edwards Lifesciences Corp.	Buy	$43.6B	-5.21%	28.0	65.86%
Abbott Laboratories	Buy	$196.2B	31.69%	34.38	13.99%
Medtronic Plc	Buy	$102.4B	-31.62%	24.43	12.06%

About Pulmonx

pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp

Organization	Pulmonx
Employees	279
CEO	Mr. David A. Lehman J.D.
Industry	Health Technology

Management People of Pulmonx

Name	Title
Mr. David A. Lehman J.D.	General Counsel & Secretary
Mr. Geoffrey Beran Rose	Chief Commercial Officer
Mr. Steven S. Williamson	CEO, President & Director
Mr. Mehul Joshi	Chief Financial Officer
Mr. Sri Radhakrishnan	Chief Technical Officer
Ms. Marcee M. Maroney	Vice President of Marketing
Sarah Huber	Vice President of Sales (U.S.)
Ms. Lisa Paul	Chief People Officer
Mr. Jérôme Erath	Senior VP & GM of Europe Middle-East & Africa
Mr. John B. McKune	VP & Corporate Controller

Important FAQs about investing in Pulmonx from India :

What is Pulmonx share price today?

Pulmonx share price today stands at $6.69, Open: $6.60 ; Previous Close: $6.55 ; High: $6.86 ; Low: $6.60 ; 52 Week High: $14.84 ; 52 Week Low: $5.46. The stock opens at $6.60, after a previous close of $6.55. The stock reached a daily high of $6.86 and a low of $6.60, with a 52-week high of $14.84 and a 52-week low of $5.46.

Can Indians buy Pulmonx shares?

Yes, Indians can invest in the Pulmonx (LUNG) from India.

With INDmoney, you can buy Pulmonx at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Pulmonx at zero transaction cost.

How can I buy Pulmonx shares from India?

It is very easy to buy Pulmonx from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Pulmonx be purchased?

Yes, you can buy fractional shares of Pulmonx with INDmoney app.

What are the documents required to start investing in Pulmonx stocks?

To start investing in Pulmonx, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Pulmonx

Today’s highest price of Pulmonx (LUNG) is $6.86.

Today’s lowest price of Pulmonx (LUNG) is $6.60.

What is today's market capitalisation of Pulmonx

Today's market capitalisation of Pulmonx LUNG is 268.1M

What is the 52 Week High and Low Range of Pulmonx

52 Week High
$14.84
52 Week Low
$5.46

What are the historical returns of Pulmonx?

1 Month Returns
2.83%
3 Months Returns
2.5%
1 Year Returns
-46.66%
5 Years Returns
-83.34%

Who is the Chief Executive Officer (CEO) of Pulmonx

Mr. David A. Lehman J.D. is the current Chief Executive Officer (CEO) of Pulmonx.

Discover More

Explore all